The study employed a sequential, two-phase design IACS-10759 concentration (i.e., 4 weeks of medication and counseling followed by 4 weeks of medication/counseling plus a contingency management procedure).

Results: Both preparation forms of methamphetamine were well-tolerated, with similar retention to placebo (0 mg, 33%; 30 mg IR, 30%, 30 mg SR, 32%). Methamphetamine SR was associated with decreased sleep and increased weight

loss. Medication adherence rates were high for the first dose of the day (95%), while adherence for subsequent capsules was lower. Those in the SR condition exhibited consistently lower rates of cocaine-positive urine samples (0 mg, 60%; 30 mg IR, 66%; 30 mg SR, 29%), p < 0.0001, and reported the greatest reduction in craving for cocaine, p < 0.05.

Conclusions: SR methamphetamine significantly reduced cocaine use and craving. Additional research is warranted to develop and evaluate agonist-like medications that may effectively treat cocaine dependence. (C) 2008 Elsevier Ireland Ltd. All rights reserved.”
“OBJECTIVE: To evaluate whether serum human epididymis protein 4 (HE4) levels could

be used as a marker to differentiate lung cancer from pulmonary tuberculosis (PTB) and as a prognostic indicator in patients with non-small-cell lung cancer (NSCLC). DESIGN: HE4 levels were measured in serum samples from 106 healthy controls, 190 lung cancer patients, 114 patients with PTB and 24 patients with pneumonia using enzyme-linked immunosorbent assay. RESULTS: Serum HE4 levels in lung cancer patients were significantly higher than those in patients with PTB selleckchem and healthy controls (P < 0.001). Using the optimal cut-off value of 94.01 pmol/1, HE4 levels distinguished lung cancer from PTB with a sensitivity of 61.6% and a specificity of 93.0%. After adjusting for

age and smoking status, a binary unconditional logistic regression model provided a sensitivity of 67.4% www.sellecn.cn/products/Everolimus(RAD001).html and a specificity of 86.0% for differentiating between these two diseases. In the NSCLC group, serum HE4 levels were significantly higher in patients at advanced stages (Stage I-II vs. Stage III-IV, P = 0.02). Higher levels of serum HE4 (83.90 pmol/1) were significantly correlated with a worse 3-year survival rate for patients with NSCLC (P < 0.05). CONCLUSION: Serum HE4 may be used as a potential marker to differentiate lung cancer from PTB and healthy controls. In addition, higher levels of HE4 predict poor prognosis in NSCLC patients.”
“Background: Drug addiction researchers have begun to study dopamine partial agonists as potential therapeutic agents. The partial dopamine D(2) receptor agonist aripiprazole has recently been tested as a treatment for stimulant and alcohol dependence in both animal and clinical Studies.

Methods: A randomized and placebo-controlled pilot clinical study was conducted in a population of Chinese light and heavy smokers to assess the effect of aripiprazole on various responses to smoking.